Monitoring one-year compliance to antihypertension medication in the Seychelles.
OBJECTIVE
To examine the compliance to medication among newly diagnosed hypertensive patients screened from the general population of the Seychelles, a rapidly developing country.


METHODS
Among the 1067 participants to a population-based survey for cardiovascular risk factors, hypertension was discovered in 50 (previously unaware of having hypertension and having blood pressure > or = 160/95 mmHg over 3 visits). These 50 patients were placed on a daily one-pill regimen of medication (bendrofluazide, atenolol, or a combination of hydrochlorothiazide and atenolol) and compliance to the regimen was assessed over 12 months using electronic pill containers. Satisfactory compliance was defined as taking the medication on 6 or 7 days a week on average (which corresponds to a mean compliance level of > or = 86%).


RESULTS
In the first month, fewer than half (46%) of the new hypertension patients achieved satisfactory compliance, and only about one-quarter (26%) achieved this level by the twelfth month. Compliance was better among the 23 participants who regularly attended medical follow-up, with nearly three-quarters of these patients (74%) achieving satisfactory compliance during the first month and over one-half (55%) by the twelfth month. There was a direct association between mean 12-month compliance level and having a highly skilled occupation; having good health awareness; and regularly attending medical appointments. In contrast, there was an inverse relationship between mean compliance level and heavy drinking.


CONCLUSIONS
The low proportion of people selected from the general population who were capable of sustaining satisfactory compliance to antihypertension medication may correspond to the maximum effectiveness of medication interventions based on a screening and treatment strategy in the general population. The results stress the need for both high-risk and population approaches to improve hypertension control.
Bovet
Pascal
P
Institut Universitaire de Médecine Sociale et Préventive, Lausanne, Switzerland. pascal.bovet@inst.hospvd.ch
Burnier
Michel
M
Madeleine
George
G
Waeber
Bernard
B
Paccaud
Fred
F
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001262:Atenolol / Q000008:administration & dosage; D001539:Bendroflumethiazide / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D016903:Drug Monitoring; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009819:Office Visits; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012646:Self Administration / Q000706:statistics & numerical data*; D012750:Seychelles / Q000453:epidemiology
D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D001262:Atenolol; D001539:Bendroflumethiazide